Petmed Express, Inc. · NASDAQ:PETS
Petmed Express — Q2 2024 Earnings Presentation
10 slides from Petmed Express's earnings presentation, Oct 30, 2023
Slide 1: 2Q24 Earnings Call
NASDAQ: PETS 2Q24 Earnings Call October 2023
Slide 2: Safe Harbor & Non-GAAP Measures
Safe Harbor & Non-GAAP Measures This Presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended
Slide 3: Quarterly Results Overview
Quarterly Results Overview Founded in 1996, PetMeds is “Your Trusted Pet Health Expert” providing fast, easy and helpful service to over 11 million customers across the U.S. NASDAQ: PETS Share Price1 $9.36 Market Cap1 $198.2M Fiscal Second Quarter Highlights FY 2023 Revenue $256.9M • $71.0 million i
Slide 4: Pet Health Expert Playbook
Pet Health Expert Playbook Transforming from a medication retailer to your trust pet health expert • Integrate and execute newly acquired businesses and partnerships Nutrition Care • Sell more products and services to a large, existing customer base • Drive year-over-year increases in new Medication
Slide 5: Financial Overview
FINANCIAL OVERVIEW
Slide 6: Select Financials
Select Financials 3 Months Ended September 30, $ in Millions 2023 2022 Sales $71.0 $65.4 Gross Profit $20.1 $18.5 Operating Expenses ($20.5) ($15.5) Adj. EBITDA1 $3.2 $7.1 Net Income ($0.1) $2.6 Dividend Paid $0.30 $0.30 Cash & Cash Equivalents $53.5 $96.5 Year-over-year revenue and gross margin gro
Slide 7: Capital Allocation Strategy
Capital Allocation Strategy Organic Inorganic Return to Growth Growth Shareholders Working Alliances & Share Capex Acquisitions Dividends Capital Partnerships Repurchases 7
Slide 8: Investment Highlights
Investment Highlights Increasing revenue is key to transition to a growth- focused business Strategic plan: integrate PetCareRx and other new partnerships, expand new customers, provide more products and deliver unique and differentiated services Continued investments in recurring revenue initiative
Slide 9: www.petmeds.com
Company Christine Chambers Chief Financial Officer 561-526-4444 Investor Relations Brian M. Prenoveau, CFA MZ Group 561-489-5315 investor@petmeds.com www.petmeds.com
Slide 10: Non-GAAP Reconciliation
Non-GAAP Reconciliation Three Months Ended September September 30, 30, $ % ($ in thousands, except percentages) 2023 2022 Change Change Consolidated Reconciliation of GAAP Net (Loss) Income to Adjusted EBITDA: Net (loss) income $ (70) $ 2,579 $ (2,649) (103) % Add (subtract): Share-based Compensatio